Tag Archives: ilmn

Illumina Falls On HiSeq Rival; Bio-Reference Up on Q2

Genomics firm Illumina (ILMN) dipped Monday on news of a competing high-end gene sequencer, while lower-end rival Bio-Reference Laboratories (BRLI) rose despite missing quarterly expectations. At the European Human Genetics Conference over the weekend, Complete Genomics, a unit of BGI (formerly Beijing Genomics Institute), previewed its Revolocity sequencing system, a “supersequencer” designed to deliver as many as 30,000 whole genome sequences

Meet 8 Hot Med Stocks Among IBD’s Big Cap Leaders

IBD’s Big Cap Leaders screen filters through highly liquid, large-cap stocks with a strong record of earnings growth. Eight top-notch medical stocks that made the screen’s cut are Valeant Pharmaceuticals (VRX), Gilead Sciences (GILD), Celgene (CELG), Actavis (ACT), Biogen (BIIB), Regeneron (REGN), Shire (SHPG) and Illumina (ILMN). Valeant Pharmaceuticals has a highest-possible IBD Composite Rating of 99, meaning its shares outperform 99% of all

Illumina Q4 Results Trigger Price Target Increases

Wedbush Securities and Maxim Group raised Illumina’s (ILMN) price targets a day after the maker of gene-sequencing systems reported fourth-quarter earnings that beat analysts’ views on a huge rise in EPS. Wedbush noted in a Jan. 28 post-earnings report that Illumina turned in Q4 results that showed its gene-sequencing business was doing even better than its pre-announcement of quarterly sales had suggested. The company pre-announced Q4 sales of